Drug Trial Radar · NCT02294682
A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Last checked: Nov 20, 2026Latest source record: May 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Apr 15, 2015
Primary completion
Jul 1, 2016
Study completion Jul 27, 2016
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GSK2140944 has demonstrated in vitro activity against Neisseria (N.) gonorrhoeae, including ciprofloxacin resistant and susceptible strains. This study is a Phase II, randomized, multicenter, open-label, dose ranging study designed to inform the optimal oral dose of GSK2140944 by further characterizing the efficacy, safety, and tolerability in subjects with uncomplicated urogenital gonorrhea due to N. gonorrhoeae. Subjects will be randomly assigned to receive either a single 1500 milligrams (mg) or 3000 mg oral dose of GSK2140944. Appropriate safety and microbiological assessments will be conducted at the Baseline (Day 1) Visit and repeated at the Test-of-Cure (Day 4 to 8) Visit. The study duration will be approximately 1 week. Approximately 60 microbiologically evaluable subjects (30 subjects in each treatment arm) will complete the study if both arms remain active throughout the study.
Conditions
- Gonorrhea
Interventions
GSK2140944Drug
Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure VisitTime frame: Baseline (Day 1, pre-dose) and Test-of-Cure visit (Day 4 to 8)
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Jenkintown, Pennsylvania
GSK Investigational Site
San Juan, Puerto Rico
GSK Investigational Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.